pioglitazone has been researched along with Arteriosclerosis, Coronary in 35 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone ameliorates insulin resistance, but has an adverse effect of oedema that may result in subsequent heart failure, especially in diabetic patients with coronary artery disease." | 9.17 | Effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone system and natriuretic peptides in diabetic patients with coronary artery disease. ( Dohi, Y; Ishibashi, K; Iwasaki, T; Kihara, Y; Kurisu, S; Mitsuba, N; Nishioka, K, 2013) |
| "In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study." | 9.15 | Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression o ( Bayturan, O; Kupfer, S; Lavoie, A; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Tuzcu, EM; Uno, K; Wolski, K, 2011) |
| "Pioglitazone added to successful statin therapy may be beneficial for coronary artery disease (CAD) patients without diabetes mellitus." | 9.13 | Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease. ( Horibata, Y; Matsuzawa, Y; Nozaki, T; Ogawa, H; Sugamura, K; Sugiyama, S, 2008) |
| "To test the hypothesis that pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, will improve endothelial function in non-diabetic subjects with coronary artery disease, we conducted a prospective study to evaluate the effect of this medication on the brachial artery vasomotor function and circulating markers of endothelial activation." | 9.12 | Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. ( Ambrose, J; Bernaski, E; Coppola, J; El-Khally, Z; Kurian, D; Mandadi, V; Morlote, M; Pinassi, E; Staniloae, C, 2007) |
| "To evaluate the effects of pioglitazone on insulin sensitivity and levels of biomarkers associated with thrombotic risk in overweight and obese, non-diabetic subjects with coronary artery disease." | 9.12 | Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. ( Dodis, R; Francis, CW; Gerich, JE; Kaba, NK; Lee, M; Messing, S; Mieszczanska, H; Phipps, RP; Schwarz, KQ; Smith, BH; Taubman, MB, 2007) |
| "Twenty-six consecutive patients with type 2 diabetes mellitus (DM) or impaired glucose tolerance (IGT) undergoing percutaneous coronary intervention (PCI) were enrolled." | 6.75 | Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. ( Kobayashi, Y; Komiyama, N; Komuro, I; Kuroda, N; Nakayama, T; Namikawa, S; Yokoyama, M, 2010) |
| "Treatment with pioglitazone increased adiponectin levels from an average of 10." | 6.73 | Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease. ( Coppola, JT; Mailloux, LM; Mindrescu, C; Patel, SR; Staniloae, CS, 2008) |
| "Pioglitazone was also found to increase significantly the apo A1 levels in patients with hyperinsulinemia, but there was no significant increase in patients given both atorvastatin and pioglitazone." | 6.73 | Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia. ( Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U, 2007) |
| "Pioglitazone treatment in non-diabetic patients with CAD was associated with a significantly better coronary endothelial function compared to placebo." | 6.73 | Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. ( Höher, M; Hombach, V; Kestler, HA; Koenig, W; Marx, N; Nusser, T; Wöhrle, J, 2008) |
| "Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT." | 5.37 | Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. ( Bahouth, SW; Cheema, P; Fain, JN; Garrett, E; Sacks, HS; Samaha, J; Wolf, RY; Wolford, D, 2011) |
| "The study population included 121 DM patients with coronary artery disease and they were randomly assigned to 60 patients taking 15 mg of pioglitazone daily in addition to their diabetic medications and 61 patients with placebo after the index procedure with drug-eluting stents (DESs)." | 5.17 | Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation. ( Cha, KS; Choi, JH; Hong, TJ; Kim, BW; Kim, SP; Lee, HC; Lee, HW; Oh, JH; Park, JH; Park, JS; Song, S; Yang, MJ, 2013) |
| "Pioglitazone ameliorates insulin resistance, but has an adverse effect of oedema that may result in subsequent heart failure, especially in diabetic patients with coronary artery disease." | 5.17 | Effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone system and natriuretic peptides in diabetic patients with coronary artery disease. ( Dohi, Y; Ishibashi, K; Iwasaki, T; Kihara, Y; Kurisu, S; Mitsuba, N; Nishioka, K, 2013) |
| "In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study." | 5.15 | Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression o ( Bayturan, O; Kupfer, S; Lavoie, A; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Tuzcu, EM; Uno, K; Wolski, K, 2011) |
| " In this study, we administered pioglitazone and pitavastatin for 16 weeks to 18 patients who had type 2 diabetes complicated by dyslipidemia and then investigated the influence of these 2 drugs on MDA-LDL(i." | 5.15 | [Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes]. ( Hayashi, S; Taguchi, A, 2011) |
| "Pioglitazone added to successful statin therapy may be beneficial for coronary artery disease (CAD) patients without diabetes mellitus." | 5.13 | Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease. ( Horibata, Y; Matsuzawa, Y; Nozaki, T; Ogawa, H; Sugamura, K; Sugiyama, S, 2008) |
| "To test the hypothesis that pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, will improve endothelial function in non-diabetic subjects with coronary artery disease, we conducted a prospective study to evaluate the effect of this medication on the brachial artery vasomotor function and circulating markers of endothelial activation." | 5.12 | Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. ( Ambrose, J; Bernaski, E; Coppola, J; El-Khally, Z; Kurian, D; Mandadi, V; Morlote, M; Pinassi, E; Staniloae, C, 2007) |
| "To evaluate the effects of pioglitazone on insulin sensitivity and levels of biomarkers associated with thrombotic risk in overweight and obese, non-diabetic subjects with coronary artery disease." | 5.12 | Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. ( Dodis, R; Francis, CW; Gerich, JE; Kaba, NK; Lee, M; Messing, S; Mieszczanska, H; Phipps, RP; Schwarz, KQ; Smith, BH; Taubman, MB, 2007) |
| "The aim of this study was to evaluate the effect of pioglitazone on nitric oxide in patients with type 2 diabetes and coronary artery disease." | 3.74 | The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus. ( Itoh, S; Katagiri, T; Kobayashi, Y; Kodama, Y; Konno, N; Nishio, K; Satoh, R; Shigemitsu, M, 2008) |
| "Pioglitazone treatment reduced HbA1c levels to a similar degree as conventional treatment (pioglitazone group 6." | 2.87 | Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial. ( Hikichi, Y; Horiuchi, K; Inoue, T; Iwasaki, Y; Kawaguchi, A; Kawasaki, T; Komukai, S; Nakao, K; Nakashima, H; Node, K; Shibata, Y; Shimomura, M; Tago, M; Tamashiro, M; Tanaka, A; Toyoda, S; Ueno, T; Yokoi, H, 2018) |
| "Twenty-six consecutive patients with type 2 diabetes mellitus (DM) or impaired glucose tolerance (IGT) undergoing percutaneous coronary intervention (PCI) were enrolled." | 2.75 | Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. ( Kobayashi, Y; Komiyama, N; Komuro, I; Kuroda, N; Nakayama, T; Namikawa, S; Yokoyama, M, 2010) |
| "Pioglitazone has a preventive effect on cardiovascular disease, but its ability to stabilize coronary plaque is unknown." | 2.74 | Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. ( Hirata, K; Kato, H; Kawamori, H; Miyoshi, N; Ogasawara, D; Otake, H; Sawada, T; Shinke, T; Shite, J; Tanino, Y; Watanabe, S, 2009) |
| "Treatment with pioglitazone increased adiponectin levels from an average of 10." | 2.73 | Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease. ( Coppola, JT; Mailloux, LM; Mindrescu, C; Patel, SR; Staniloae, CS, 2008) |
| "Pioglitazone was also found to increase significantly the apo A1 levels in patients with hyperinsulinemia, but there was no significant increase in patients given both atorvastatin and pioglitazone." | 2.73 | Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia. ( Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U, 2007) |
| "Pioglitazone treatment in non-diabetic patients with CAD was associated with a significantly better coronary endothelial function compared to placebo." | 2.73 | Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. ( Höher, M; Hombach, V; Kestler, HA; Koenig, W; Marx, N; Nusser, T; Wöhrle, J, 2008) |
| "The prevalence of type 2 diabetes mellitus (T2DM) is growing at an alarming rate and reaching epidemic proportions, and cardiovascular disease continues to be one of the leading causes of death in the United States." | 2.44 | PPARgamma agonists and coronary atherosclerosis. ( Chilton, R; Sulistio, MS; Thukral, N; Zion, A, 2008) |
| "Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT." | 1.37 | Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. ( Bahouth, SW; Cheema, P; Fain, JN; Garrett, E; Sacks, HS; Samaha, J; Wolf, RY; Wolford, D, 2011) |
| "Because coronary artery disease is a major complication for such patients, it is important to determine the effects of PPARgamma activation on arteriosclerosis." | 1.31 | Antiinflammatory and antiarteriosclerotic effects of pioglitazone. ( Egashira, K; Hiasa, K; Ichiki, T; Inoue, S; Ishibashi, M; Kitamoto, S; Ni, W; Takeshita, A; Usui, M; Zhao, Q, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (48.57) | 29.6817 |
| 2010's | 17 (48.57) | 24.3611 |
| 2020's | 1 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, Y | 1 |
| Ji, JJ | 1 |
| Wang, XD | 1 |
| Sun, XJ | 1 |
| Li, M | 1 |
| Wei, Q | 1 |
| Ren, LQ | 1 |
| Liu, NF | 1 |
| Tanaka, A | 1 |
| Komukai, S | 1 |
| Shibata, Y | 1 |
| Yokoi, H | 1 |
| Iwasaki, Y | 1 |
| Kawasaki, T | 1 |
| Horiuchi, K | 1 |
| Nakao, K | 1 |
| Ueno, T | 1 |
| Nakashima, H | 1 |
| Tamashiro, M | 1 |
| Hikichi, Y | 1 |
| Shimomura, M | 1 |
| Tago, M | 1 |
| Toyoda, S | 1 |
| Inoue, T | 1 |
| Kawaguchi, A | 1 |
| Node, K | 1 |
| Lee, HW | 1 |
| Lee, HC | 1 |
| Kim, BW | 1 |
| Yang, MJ | 1 |
| Park, JS | 1 |
| Oh, JH | 1 |
| Choi, JH | 1 |
| Cha, KS | 1 |
| Hong, TJ | 1 |
| Kim, SP | 1 |
| Song, S | 1 |
| Park, JH | 2 |
| Nitta, Y | 1 |
| Tahara, N | 1 |
| Tahara, A | 1 |
| Honda, A | 1 |
| Kodama, N | 1 |
| Mizoguchi, M | 1 |
| Kaida, H | 1 |
| Ishibashi, M | 2 |
| Hayabuchi, N | 1 |
| Ikeda, H | 1 |
| Yamagishi, S | 1 |
| Imaizumi, T | 1 |
| Christoph, M | 1 |
| Herold, J | 1 |
| Berg-Holldack, A | 1 |
| Rauwolf, T | 1 |
| Ziemssen, T | 1 |
| Schmeisser, A | 1 |
| Weinert, S | 1 |
| Ebner, B | 1 |
| Said, S | 1 |
| Strasser, RH | 1 |
| Braun-Dullaeus, RC | 1 |
| Zhang, MD | 1 |
| Zhang, YH | 1 |
| Zhu, EJ | 1 |
| Qiao, SB | 1 |
| Lv, SZ | 1 |
| Zhao, QM | 1 |
| Mani, P | 1 |
| Uno, K | 2 |
| St John, J | 1 |
| Kupfer, S | 2 |
| Perez, A | 3 |
| Tuzcu, EM | 2 |
| Hazen, SL | 1 |
| Nissen, SE | 2 |
| Nicholls, SJ | 2 |
| Sugamura, K | 1 |
| Sugiyama, S | 1 |
| Matsuzawa, Y | 1 |
| Nozaki, T | 1 |
| Horibata, Y | 1 |
| Ogawa, H | 1 |
| Patel, SR | 1 |
| Mailloux, LM | 1 |
| Coppola, JT | 1 |
| Mindrescu, C | 1 |
| Staniloae, CS | 1 |
| Shah, R | 1 |
| Fresco, C | 1 |
| Nakayama, T | 1 |
| Komiyama, N | 1 |
| Yokoyama, M | 1 |
| Namikawa, S | 1 |
| Kuroda, N | 1 |
| Kobayashi, Y | 2 |
| Komuro, I | 1 |
| Marx, N | 2 |
| Nishio, K | 1 |
| Shigemitsu, M | 1 |
| Kodama, Y | 1 |
| Itoh, S | 1 |
| Konno, N | 1 |
| Satoh, R | 1 |
| Katagiri, T | 1 |
| Ogasawara, D | 1 |
| Shite, J | 1 |
| Shinke, T | 1 |
| Watanabe, S | 1 |
| Otake, H | 1 |
| Tanino, Y | 1 |
| Sawada, T | 1 |
| Kawamori, H | 1 |
| Kato, H | 1 |
| Miyoshi, N | 1 |
| Hirata, K | 1 |
| Clementi, F | 1 |
| Di Luozzo, M | 1 |
| Mango, R | 1 |
| Luciani, G | 1 |
| Trivisonno, A | 1 |
| Pizzuto, F | 1 |
| Martuscelli, E | 1 |
| Mehta, JL | 1 |
| Romeo, F | 1 |
| Davidson, MH | 1 |
| Beam, CA | 1 |
| Haffner, S | 1 |
| D'Agostino, R | 1 |
| Mazzone, T | 1 |
| Zhao, Y | 1 |
| He, X | 1 |
| Huang, C | 1 |
| Fu, X | 1 |
| Shi, X | 1 |
| Wu, Y | 2 |
| Han, Y | 1 |
| Li, N | 1 |
| Heng, CK | 1 |
| Hong, SJ | 1 |
| Kim, ST | 1 |
| Kim, TJ | 1 |
| Kim, EO | 1 |
| Ahn, CM | 1 |
| Kim, JS | 1 |
| Lee, KM | 1 |
| Lim, DS | 1 |
| Wolski, K | 1 |
| Bayturan, O | 1 |
| Lavoie, A | 1 |
| Nesto, R | 1 |
| Taguchi, A | 1 |
| Hayashi, S | 1 |
| Khera, AV | 1 |
| Cuchel, M | 1 |
| de la Llera-Moya, M | 1 |
| Rodrigues, A | 1 |
| Burke, MF | 1 |
| Jafri, K | 1 |
| French, BC | 1 |
| Phillips, JA | 1 |
| Mucksavage, ML | 1 |
| Wilensky, RL | 1 |
| Mohler, ER | 1 |
| Rothblat, GH | 1 |
| Rader, DJ | 1 |
| Esposito, K | 1 |
| Maiorino, MI | 1 |
| Di Palo, C | 1 |
| Gicchino, M | 1 |
| Petrizzo, M | 1 |
| Bellastella, G | 1 |
| Saccomanno, F | 1 |
| Giugliano, D | 1 |
| Sacks, HS | 1 |
| Fain, JN | 1 |
| Cheema, P | 1 |
| Bahouth, SW | 1 |
| Garrett, E | 1 |
| Wolf, RY | 1 |
| Wolford, D | 1 |
| Samaha, J | 1 |
| Bell, DS | 1 |
| O'Keefe, JH | 1 |
| Kurisu, S | 1 |
| Iwasaki, T | 1 |
| Ishibashi, K | 1 |
| Mitsuba, N | 1 |
| Dohi, Y | 1 |
| Nishioka, K | 1 |
| Kihara, Y | 1 |
| Egashira, K | 1 |
| Hiasa, K | 1 |
| Inoue, S | 1 |
| Ni, W | 1 |
| Zhao, Q | 1 |
| Usui, M | 1 |
| Kitamoto, S | 1 |
| Ichiki, T | 1 |
| Takeshita, A | 1 |
| Staniloae, C | 1 |
| Mandadi, V | 1 |
| Kurian, D | 1 |
| Coppola, J | 1 |
| Bernaski, E | 1 |
| El-Khally, Z | 1 |
| Morlote, M | 1 |
| Pinassi, E | 1 |
| Ambrose, J | 1 |
| Mieszczanska, H | 1 |
| Kaba, NK | 1 |
| Francis, CW | 1 |
| Gerich, JE | 1 |
| Dodis, R | 1 |
| Schwarz, KQ | 1 |
| Phipps, RP | 1 |
| Smith, BH | 1 |
| Lee, M | 1 |
| Messing, S | 1 |
| Taubman, MB | 1 |
| Forst, T | 1 |
| Karagiannis, E | 1 |
| Lübben, G | 1 |
| Hohberg, C | 1 |
| Schöndorf, T | 1 |
| Dikta, G | 1 |
| Drexler, M | 1 |
| Morcos, M | 1 |
| Dänschel, W | 1 |
| Borchert, M | 1 |
| Pfützner, A | 1 |
| Douglas, JS | 1 |
| Mehta, A | 1 |
| Shah, U | 1 |
| Parikh, K | 1 |
| Chag, M | 1 |
| Baxi, H | 1 |
| Chandarana, A | 1 |
| Naik, A | 2 |
| Shah, K | 1 |
| Goyal, R | 1 |
| Bourassa, MG | 1 |
| Berry, C | 1 |
| Sulistio, MS | 1 |
| Zion, A | 1 |
| Thukral, N | 1 |
| Chilton, R | 1 |
| Wöhrle, J | 1 |
| Koenig, W | 1 |
| Hombach, V | 1 |
| Kestler, HA | 1 |
| Höher, M | 1 |
| Nusser, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631] | 70 participants (Actual) | Interventional | 2007-05-31 | Completed | |||
| International Multicenter Trial on the Prognostic Value of Arterial 18F-FDG PET Imaging in Patients With History of Myocardial Infarction[NCT05138718] | 2,041 participants (Anticipated) | Observational [Patient Registry] | 2021-12-01 | Recruiting | |||
| Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent[NCT00376870] | Phase 3 | 160 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| A Double-Blind, Randomized, Comparator-Controlled Study In Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultr[NCT00225277] | Phase 3 | 547 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Due to low event rates, number of subjects experiencing any of the composite endpoint A cardiovascular events is being reported instead of time to first occurrence. Endpoint A conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | Participants (Number) |
|---|---|
| Pioglitazone QD | 5 |
| Glimepiride QD | 6 |
Due to low event rates, number of subjects experiencing any of the composite endpoint B cardiovascular events is being reported instead of time to first occurrence. Endpoint B conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | Participants (Number) |
|---|---|
| Pioglitazone QD | 40 |
| Glimepiride QD | 41 |
Due to low event rates, number of subjects experiencing any of the composite endpoint C cardiovascular events is being reported instead of time to first occurrence. Endpoint C conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone QD | 11 |
| Glimepiride QD | 13 |
The nominal change in normalized total atheroma volume as measured by the average of plaque areas for all slices of anatomically comparable segments of the target coronary artery multiplied by the mean number of matched slices in the population. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)
| Intervention | Percent volume (Least Squares Mean) | |
|---|---|---|
| Baseline | Nominal Change from Baseline | |
| Glimepiride QD | 217.619 | -1.480 |
| Pioglitazone QD | 206.579 | -5.528 |
The nominal change from baseline in percent atheroma volume for all slices of anatomically comparable segments of the target coronary artery. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)
| Intervention | Percent volume (Least Squares Mean) | |
|---|---|---|
| Baseline | Nominal Change from Baseline | |
| Glimepiride QD | 40.016 | 0.725 |
| Pioglitazone QD | 40.592 | -0.161 |
The incidence of cardiovascular events and composite endpoints occurring within 30 days of last dose as adjudicated by the Clinical Endpoint Committee. Abbreviations: PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; CHF: Congestive Heart Failure. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | Number of Events (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonfatal Myocardial Infarction | Nonfatal Stroke | Coronary Revascularization: PCI/CABG counted once | Coronary Revascularization: PCI | Coronary Revascularization: CABG | Carotid Endarterectomy/Stenting | Hospitalization for Unstable Angina | CHF Hospitalization: new/exacerbated counted once | Hospitalization for New CHF | Hospitalization for Exacerbated CHF | Noncardiovascular Mortality | Cardiovascular Mortality | Composite Endpoint A | Composite Endpoint B | Composite Endpoint C | |
| Glimepiride QD | 4 | 1 | 30 | 28 | 2 | 0 | 2 | 5 | 2 | 3 | 1 | 1 | 6 | 41 | 13 |
| Pioglitazone QD | 2 | 0 | 29 | 25 | 5 | 1 | 4 | 4 | 4 | 0 | 0 | 3 | 5 | 40 | 11 |
4 reviews available for pioglitazone and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Effect of pioglitazone on in-stent restenosis after coronary drug-eluting stent implantation: a meta-analysis of randomized controlled trials.
Topics: Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Humans; Hypoglycemic Agents; Piog | 2014 |
The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis.
Topics: C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; | 2010 |
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease | 2007 |
PPARgamma agonists and coronary atherosclerosis.
Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopath | 2008 |
20 trials available for pioglitazone and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial.
Topics: Administration, Oral; Biomarkers; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Coro | 2018 |
Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation.
Topics: Aged; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Hypoglycemi | 2013 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Agents; Coronary Artery Disease; Coronary Vessels; Dis | 2015 |
Favorable Impact on LDL Particle Size in Response to Treatment With Pioglitazone is Associated With Less Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes.
Topics: Biological Availability; Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Hu | 2015 |
Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease.
Topics: Adiponectin; Aged; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, HDL; Coronary Artery Di | 2008 |
Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Brachial Artery; Coronary Artery Disease; Cross-Over St | 2008 |
Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound.
Topics: Aged; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow- | 2010 |
Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Blood Glucose; C-Reactive Protein; Coronary Artery Disease; Coronary Vessels; Dia | 2009 |
Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.
Topics: Aged; Calcinosis; Carotid Artery Diseases; Chi-Square Distribution; Coronary Artery Disease; Diabete | 2010 |
Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Glucose; Cardiovascular Agents; Cell | 2010 |
Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression o
Topics: Atherosclerosis; Cholesterol, HDL; Coronary Artery Disease; Coronary Stenosis; Diabetes Mellitus, Ty | 2011 |
[Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes].
Topics: Aged; Arteriosclerosis; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Ty | 2011 |
Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
Topics: Adult; Aged; Body Mass Index; Cell Survival; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dia | 2011 |
Effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone system and natriuretic peptides in diabetic patients with coronary artery disease.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Coronary Artery Disease; Diabetes Mellitus, Type 2 | 2013 |
Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease.
Topics: Adult; Aged; Arginine; Blood Sedimentation; Brachial Artery; C-Reactive Protein; Cardiovascular Agen | 2007 |
Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease.
Topics: Adult; Aged; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Fasting; Female; Hemo | 2007 |
Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease.
Topics: Aged; Anti-Inflammatory Agents; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Artery Disea | 2008 |
Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HD | 2007 |
Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease.
Topics: Coronary Artery Disease; Diabetes Complications; Double-Blind Method; Endothelium, Vascular; Female; | 2008 |
11 other studies available for pioglitazone and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Periostin promotes arterial calcification through PPARγ-related glucose metabolism reprogramming.
Topics: Animals; Aorta, Thoracic; Apoptosis; Cell Adhesion Molecules; Computed Tomography Angiography; Coron | 2021 |
Pioglitazone vs glimepiride in the PERISCOPE trial.
Topics: Atherosclerosis; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; H | 2008 |
Pioglitazone vs glimepiride in the PERISCOPE trial.
Topics: Atherosclerosis; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-C | 2008 |
PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents | 2008 |
The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Diabetes Mellitus, Type 2; Enzyme-Lin | 2008 |
Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combinatio | 2009 |
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.
Topics: Aged; Biological Transport; Carotid Arteries; Case-Control Studies; Cholesterol; Coronary Artery Dis | 2011 |
Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Interleukin 1 Recep | 2011 |
Lowering the triglyceride/high-density lipoprotein cholesterol and its association with the beneficial impact of pioglitazone on coronary atherosclerosis in the PERISCOPE study is likely due to lowering insulin resistance.
Topics: Cholesterol, HDL; Coronary Artery Disease; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglita | 2011 |
Antiinflammatory and antiarteriosclerotic effects of pioglitazone.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Blood Glucose; Blood Pressure; Chemokine CCL2; | 2002 |
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Melli | 2008 |